Clinical reference Biomarker Directory
Back to directory

NPM1

Established

NPM1 mutation is the most common AML genetic abnormality and, in isolation, one of the most favorable prognostic markers.

Also known as NPM1 nucleophosmin 1 NPM1c
In plain language

NPM1 is the single most commonly mutated gene in AML, and on its own, it's actually a good sign for how a patient's leukemia is likely to behave. But when a second, less favorable mutation is also present, the outlook changes considerably — which is why doctors always look at these mutations together, not in isolation.

Biomarker & context

NPM1 (nucleophosmin 1) is a nucleolar protein involved in ribosome biogenesis and tumor suppressor regulation; mutations causing abnormal cytoplasmic localization of the protein are the single most common genetic abnormality in acute myeloid leukemia, found in roughly 30% of adult AML cases.

What it indicates

NPM1-mutated AML (without co-occurring adverse mutations) is classified as favorable risk under both 2022 and 2024 ELN criteria, with the longest reported overall survival (39 months in one analysis) among the major AML genetic subgroups when signaling gene mutations (FLT3-ITD, KRAS, NRAS) are absent.

Diagnosis & clinical testing

Detected via PCR or NGS panel on bone marrow or blood; NPM1 mutation status is now incorporated into the World Health Organization's formal AML classification as a distinct disease entity ("AML with mutated NPM1"), reflecting its central role in both diagnosis and prognosis.

Guiding treatment

NPM1 mutation status, considered together with FLT3-ITD co-mutation status, meaningfully changes treatment intensity decisions — isolated NPM1 mutation supports a more favorable treatment approach, while co-occurring FLT3-ITD or other signaling mutations shifts management toward more intensive therapy or transplant consideration given the substantially worse prognosis.

Clinical significance

Now incorporated as a distinct WHO AML disease entity; prognosis depends heavily on co-occurring mutations, especially FLT3-ITD.

References
  1. Blood. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.